Skip to search formSkip to main contentSkip to account menu

lopinavir / Ritonavir

Known as: Lopinavir+Ritonavir, Lopinavir and Ritonavir, lopinavir ritonavir 
A combination of the drugs ritonavir and lopinavir. It is used to treat infection with HIV (the virus that causes AIDS). It is also being studied in… 
National Institutes of Health

Related topics

Related topics

2 relations
Ritonavirlopinavir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial.
OBJECTIVES We evaluated a monotherapy maintenance regimen with lopinavir/ritonavir versus continuing current combined… 
Highly Cited
2009
Highly Cited
2009
Plasma 4β‐Hydroxycholesterol: An Endogenous CYP3A Metric?
We assessed the suitability of 4β‐hydroxycholesterol (4βOH‐C) as an endogenous cytochrome P450 3A (CYP3A) phenotyping metric. 4… 
Highly Cited
2009
Highly Cited
2009
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression
Background Risk factors for loss of virological response in patients receiving lopinavir/ritonavir (LPV/r) monotherapy as… 
Highly Cited
2009
Highly Cited
2009
Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy
ABSTRACT The MONARK study was a pilot randomized trial comparing the safety and efficacy of lopinavir-ritonavir (LPV/r… 
Highly Cited
2009
Highly Cited
2009
HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites.
Recent studies have demonstrated that human immunodeficiency virus (HIV) protease inhibitors (PIs) exert inhibitory effects on… 
Highly Cited
2007
Highly Cited
2007
Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States.
BACKGROUND The extent to which drug-resistant human immunodeficiency virus type 1 (HIV-1) acquired through mother-to-child… 
Review
2005
Review
2005
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results
Objective:To evaluate fosamprenavir/lopinavir (LPV)/ritonavir (RTV), fosamprenavir/RTV, or LPV/RTV in antiretroviral treatment… 
Highly Cited
2004
Highly Cited
2004
Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir
Objective: To assess the pharmacokinetic interaction of saquinavir and lopinavir/ritonavir. Design: Patients from the Frankfurt… 
Highly Cited
2004
Highly Cited
2004
Steady-State Pharmacokinetics of a Double-Boosting Regimen of Saquinavir Soft Gel plus Lopinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Infected Adults
ABSTRACT Management of treatment-experienced human immunodeficiency virus patients has become complex, and therapy may need to… 
Highly Cited
2002
Highly Cited
2002
Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics.
Lopinavir/ritonavir was administered to 35 HIV-infected patients after therapeutic failure with other protease inhibitors. The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)